checkAd
    Startseite > Aktien > MaaT Pharma > Nachrichten
    MaaT Pharma Aktie
    8,9400
     
    EUR
    +0,45 %
    +0,0400 EUR
    Letzter Kurs 09:59:02 Frankfurt
    8,9400
     
    EUR
    224 STK
    Geldkurs 09:59:03
    9,9200
     
    EUR
    202 STK
    Briefkurs 09:59:03
    ISIN: FR0012634822 · WKN: A3C7A5 · SYM: 4RD · Frankreich

    Neueste Nachrichten

    MaaT Pharma to Hold Annual General Meeting on May 28, 2024
    22.04.24 · Business Wire (engl.) · MaaT Pharma
    MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event
    15.04.24 · Business Wire (engl.) · MaaT Pharma
    MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
    09.04.24 · Business Wire (engl.) · MaaT Pharma
    MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
    08.04.24 · Business Wire (engl.) · MaaT Pharma
    MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale
    05.04.24 · Business Wire (engl.) · MaaT Pharma
    MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview
    28.03.24 · Business Wire (engl.) · MaaT Pharma
    MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer
    21.03.24 · Business Wire (engl.) · MaaT Pharma
    MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To improve Patients’ Responses to Immunotherapies
    19.03.24 · Business Wire (engl.) · MaaT Pharma
    MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference
    12.03.24 · Business Wire (engl.) · MaaT Pharma
    MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
    07.03.24 · Business Wire (engl.) · MaaT Pharma
    MaaT Pharma Releases its 2024 Financial Calendar
    07.03.24 · Business Wire (engl.) · MaaT Pharma
    MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma
    05.03.24 · Business Wire (engl.) · MaaT Pharma